We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Objects to “Stacking” Requirement in Medicaid Drug Rebate Rule
Industry Objects to “Stacking” Requirement in Medicaid Drug Rebate Rule
The big three drug associations, representing brand pharmaceuticals, generics and biotechnology, have all expressed strong objections to the CMS proposed rule for the Medicaid Drug Rebate program “stacking” requirement that revises the definition of “best price.”